HAN Jinbiao 1,2 , LI Kemin 1,2 , HU Xia 1,2 , YIN Rutie 1,2
  • 1. Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
  • 2. Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan 610041, P. R. China;
YIN Rutie, Email: yrtt2013@163.com
Export PDF Favorites Scan Get Citation

The mortality rate of ovarian cancer is the highest among female reproductive tract malignancies. Although most patients have undergone recurrent treatments such as surgery, chemotherapy, and targeted therapy, the recurrence rate is still high. The exploration of scholars in this field has never stopped. In recent years, remarkable achievements have been made in the medical treatment of ovarian cancer. The research of poly adenosinediphosphate-ribose polymerase, immunotherapy (immunocheckpoint inhibitor monotherapy, immune checkpoint inhibitor combined with other drugs) and anti-angiogenic drugs have provided new methods for the treatment of this disease, and throughout the whole process of ovarian cancer treatment. This paper summarizes this, and aims to provide a reference for the clinical treatment of ovarian cancer.

Citation: HAN Jinbiao, LI Kemin, HU Xia, YIN Rutie. Progress in medical treatment of ovarian cancer. West China Medical Journal, 2021, 36(3): 406-411. doi: 10.7507/1002-0179.201909026 Copy

  • Previous Article

    Research progress of serum C-reactive protein, prealbumin and their ratio in gastric cancer
  • Next Article

    新型冠状病毒肺炎产妇体外膜肺氧合辅助下的镇静一例